Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021
CAMBRIDGE, Mass., June 3, 2021 /PRNewswire/ -- Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced presentations of data from the global Phase 3 program for vadadustat at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress 2021, to be held June 5 - June 8, 2021.
Abstracts are now available online within Nephrology Dialysis Transplantation (NDT), the official journal for the ERA-EDTA.
Akebia-sponsored mini-oral sessions are:
For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/.
About Akebia Therapeutics
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-announces-presentations-at-era-edta-virtual-congress-2021-301304979.html
SOURCE Akebia Therapeutics
Company Codes: NASDAQ-NMS:AKBA